drugset
drugset / Trial / NCT04643886

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

NCT04643886 ↗

Phase 2 Terminated 62 enrolled Gemini Therapeutics, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.

Timeline

Start
2020-07-30
Primary completion
2022-02-18
Completion
2022-03-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject GEM103 Protein / enzyme biologic — Intravitreal

Indications

diffuse secondary choroid atrophy dry age related macular degeneration